Logo

American Heart Association

  8
  0


Final ID: Mo3003

Prevalence of Diabetes Mellitus in Calcutta Schoolteachers and its Relationship with Cardiovascular Risk as Assessed by the ASCVD Model

Abstract Body (Do not enter title and authors here): Introduction: Cardiovascular disease (CVD) is rising in prevalence in India with economic development and the adoption of a Western lifestyle.

Hypothesis: The increase in incidence and prevalence of CVD is possibly due to a rise in the incidence of risk factors like diabetes mellitus (DM), hypertension, hyperlipidemia, lack of physical activity and obesity, among various other causes.

Aims: 1. To estimate the prevalence of DM in the community of Calcutta schoolteachers
2. To examine the relationship between the prevalence of DM and CVD risk as assessed by the different traditional CVD risk factors (age, sex, hypertension, current smoking, DM, and hyperlipidemia).

Methods: We recruited 4,150 schoolteachers from 400 schools in Calcutta, India between June, and August 2019 with approval of the Tufts IRB and the local Ethics Committee. Participants were asked questions about their different risk factors to ascertain their cardiovascular risk by the ASCVD risk calculator. Baseline values (total cholesterol 170 mg/dL, HDL-C 50 mg/dL, no DM) were used when a participant’s glycemic status or lipid profile was not available. Based on the risk score, participants were stratified as mild (<5%), moderate (5-10%), or high (>10%) risk for developing ASCVD. A total of 240 participants were randomly selected from a stratified sample of the participants for evaluation for diabetes using HbA1c. DM was diagnosed when the Hb A1 C was 6.5% or more.

Results: The mean age of the participants was 44 years, and 41% were male. Out of a total of 4,150 participants, 85.7% (3,558) were in the low-risk for CVD category, 9.0% (374) were moderate-risk, and 5.3% (218) were high-risk. Among the 240 screened for DM, 17.1% (41) were found to have the condition, and 41.3% (99) were pre-diabetic. There was no significant difference in prevalence of DM between men and women in the overall study population and in the mild risk group. However, more women in the medium risk group and more men in the high-risk group were found to be diabetic (p value <0.001 in both). Some participants were reclassified based on their new diagnosis of DM.

Conclusions: The prevalence of DM was high among Calcutta schoolteachers, which contributes to being at increased risk for ASCVD. Most participants were unaware of their DM or cardiovascular risk, highlighting the need for increased testing and awareness. The estimates from this study may be used to understand the community burden of DM and cardiovascular risk.
  • Ray, Madhab  ( TUFTS UNIVERSITY SCHOOL OF MEDICINE , Andover , Massachusetts , United States )
  • Goel, Neev  ( North Attleborough High School , North Attleborough , Massachusetts , United States )
  • John, Lisa  ( Pleasant Grove High School , Elk Grove , California , United States )
  • Soohoo, Julie  ( UC Irvine , Irvine , California , United States )
  • John, Maria  ( NYIT COM , wilson Hall , Arizona , United States )
  • Sarkar, Arja  ( Northside College Prep , Chicago , Illinois , United States )
  • Gogada, Khushal  ( Independence High School , Frisco , Texas , United States )
  • Pal, Anushri  ( Acton Boxborough Regional High School , Acton , Massachusetts , United States )
  • Ghosh, Ahana  ( JSS Medical College , Mysore , India )
  • Sikder, Sonali  ( Rutgers NJMS , New Brunswick , New Jersey , United States )
  • Viswanathan, Badri  ( San Mateo High School , San Mateo , California , United States )
  • Guha, Santanu  ( Medical College, Calcutta , Calcutta , West Bengal , India )
  • Mandal, Srijan  ( Amador Valley High School , Pleasanton , California , United States )
  • Karak, Avik  ( Medical College, Calcutta , Calcutta , India )
  • Chowdhury, Basabendra  ( Medical College, Calcutta , Calcutta , India )
  • Chaudhuri, Sudipta  ( Healthy Heart Initiative , Calcutta , India )
  • Hazra, Prakash  ( Central Government Health Services , Calcutta , India )
  • Goldberg, Robert  ( UNIV OF MASSACHUSETTS MED SCHOOL , Worcester , Massachusetts , United States )
  • Bhatt, Deepak  ( Mount Sinai Fuster Heart Hospital , New York , New York , United States )
  • Selker, Harry  ( TUFTS MEDICAL CENTER , Boston , Massachusetts , United States )
  • Ray, Bipasha  ( University of Michigan , Ann Arbor , Michigan , United States )
  • Saxena, Varun  ( Emory University , Portland , Oregon , United States )
  • Menon, Rohan  ( Duke University , Durham , North Carolina , United States )
  • Desai, Virang  ( Ohio State University , Columbus , Ohio , United States )
  • Ray, Meghna  ( Emory University , Atlanta , Georgia , United States )
  • Desai, Vivaan  ( Rutgers Universtiy , New Brunswick , New Jersey , United States )
  • Sagar Dey, Trisha  ( Vydehi Institute of Medical Sciences and Research Center , Bengaluru , India )
  • Author Disclosures:
    Madhab Ray: DO NOT have relevant financial relationships | Neev Goel: No Answer | Lisa John: No Answer | Julie SooHoo: DO NOT have relevant financial relationships | Maria John: No Answer | Arja Sarkar: No Answer | Khushal Gogada: No Answer | Anushri Pal: DO NOT have relevant financial relationships | Ahana Ghosh: No Answer | Sonali Sikder: No Answer | Badri Viswanathan: No Answer | Santanu Guha: DO NOT have relevant financial relationships | Srijan Mandal: No Answer | Avik Karak: No Answer | Basabendra Chowdhury: No Answer | Sudipta Chaudhuri: No Answer | Prakash Hazra: DO NOT have relevant financial relationships | Robert Goldberg: DO NOT have relevant financial relationships | Deepak Bhatt: DO have relevant financial relationships ; Advisor:Angiowave, Bayer, Boehringer Ingelheim, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, High Enroll, Janssen, Level Ex, McKinsey, Medscape Cardiology, Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Stasys:Active (exists now) ; Other (please indicate in the box next to the company name):Trustee: American College of Cardiology; Unfunded Research: FlowCo:Active (exists now) ; Other (please indicate in the box next to the company name):Site Co-Investigator: Abbott, Biotronik, Boston Scientific, CSI, Endotronix, St. Jude Medical (now Abbott), Philips, SpectraWAVE, Svelte, Vascular Solutions;:Active (exists now) ; Royalties/Patent Beneficiary:Royalties: Elsevier (Editor, Braunwald’s Heart Disease):Active (exists now) ; Researcher:Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Alnylam, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CinCor, Cleerly, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Otsuka, Owkin, Pfizer, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, Youngene, 89Bio;:Active (exists now) ; Royalties/Patent Beneficiary:Patent: Sotagliflozin (named on a patent for sotagliflozin assigned to Brigham and Women's Hospital who assigned to Lexicon; neither I nor Brigham and Women's Hospital receive any income from this patent);:Active (exists now) ; Other (please indicate in the box next to the company name):Honoraria: Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Oakstone CME (Course Director, Comprehensive Review of Interventional Cardiology), Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), WebMD (CME steering committees), Wiley (steering committee);:Active (exists now) ; Other (please indicate in the box next to the company name):Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), CSL Behring (AHA lecture), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), K2P (Co-Chair, interdisciplinary curriculum):Active (exists now) ; Other (please indicate in the box next to the company name):Data Monitoring Committees: Acesion Pharma, Assistance Publique-Hôpitaux de Paris, Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (Chair, PEITHO trial), Cleveland Clinic, Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo; for the ABILITY-DM trial, funded by Concept Medical; for ALLAY-HF, funded by Alleviant Medical), Novartis, Population Health Research Institute; Rutgers University (for the NIH-funded MINT Trial);:Active (exists now) ; Consultant:Broadview Ventures, GlaxoSmithKline, Hims, SFJ, Youngene:Active (exists now) ; Other (please indicate in the box next to the company name):Board of Directors: American Heart Association New York City, Angiowave (stock options), Bristol Myers Squibb (stock), DRS.LINQ (stock options), High Enroll (stock);:Active (exists now) | Harry Selker: No Answer | Bipasha Ray: DO NOT have relevant financial relationships | Varun Saxena: No Answer | Rohan Menon: No Answer | Virang Desai: No Answer | Meghna Ray: No Answer | Vivaan Desai: No Answer | Trisha Sagar Dey: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

What’s New in Cardiovascular Outcomes in Diabetes

Monday, 11/18/2024 , 10:30AM - 11:30AM

Abstract Poster Session

More abstracts on this topic:
Age and Sex Multiplicatively Moderate the Association of Daily Sedentary Time with Depressive Symptoms in Rural Patients with Cardiovascular Diseases

Kang Junghee, Moser Debra, Cha Geunyeong, Lin Chin-yen, Wu Jia-rong, Okoli Chizimuzo, Latimer Abigail, Lennie Terry, Biddle Martha, Chung Misook

A Randomized Phase 2 Trial of Muvalaplin: An Oral Disrupter of the Assembly of Lipoprotein(a) Particles

Nicholls Stephen, Ni Wei, Rhodes Grace, Nissen Steven, Navar Ann Marie, Michael Laura, Krege John

More abstracts from these authors:
You have to be authorized to contact abstract author. Please, Login
Not Available